Abstract
P-glycoprotein (P-gp) at the blood-brain barrier (BBB) functions as an active efflux pump by extruding a wide range of substrates from the brain. This is important for maintaining loco-regional homeostasis and for protecting the brain against blood-borne toxic substances. Altered P-gp function seems to be involved in the pathophysiology of neurodegenerative disease and various neurological and psychiatric disorders. Positron emission tomography (PET) with the radiotracer 11C-verapamil (VPM-PET) is a validated technique allowing measurement of P-gp function at the human BBB. In this review, we highlight changes of P-gp function, as measured with VPM-PET, in aging and in the pathogenesis and progression of neurodegenerative disease, as well as their role in depressive disorders.
Keywords: P-glycoprotein, Blood-Brain Barrier, Ageing, Depression, Parkinson's Disease, Alzheimer's Disease, Positron Emission Tomography (PET), Verapamil, C-verapamil, P-glycoprotein (P-gp), Blood-brain barrier (BBB), (MRP), Central nervous system (CNS), Amyotrophic lateral sclerosis, Single-photon emission computed tomography, Tariquidar, P-gp expression, CD4+ and CD8+ T Cells, Statistical parametric mapping (SPM), Neurodegenerative disease, β-amyloid, ß-amyloid precursor protein (APP), ß-site APP cleaving enzyme (BACE), Lipoprotein receptor related protein 1 (LRP1), Cerebral amyloid angiopathy (CAA), P-gp inhibitor, Rifampicin, GSK188909, α-synuclein oligomers, C3435T TT polymorphism, Progressive supranuclear palsy (PSP), Multisystem atrophy (MSA), Pergolide, pramipexol, budipine, Huntington disease (HD), Creutzfeldt-Jakob Disease (CJD), Amyotrophic lateral sclerosis (ALS), Major depressive disorder (MDD)
Current Topics in Medicinal Chemistry
Title: 11C-verapamil to Assess P-gp Function in Human Brain During Aging,Depression and Neurodegenerative Disease
Volume: 10 Issue: 17
Author(s): A. L. Bartels, O. L. de Klerk, R. Kortekaas, J. J. de Vries and K. L. Leenders
Affiliation:
Keywords: P-glycoprotein, Blood-Brain Barrier, Ageing, Depression, Parkinson's Disease, Alzheimer's Disease, Positron Emission Tomography (PET), Verapamil, C-verapamil, P-glycoprotein (P-gp), Blood-brain barrier (BBB), (MRP), Central nervous system (CNS), Amyotrophic lateral sclerosis, Single-photon emission computed tomography, Tariquidar, P-gp expression, CD4+ and CD8+ T Cells, Statistical parametric mapping (SPM), Neurodegenerative disease, β-amyloid, ß-amyloid precursor protein (APP), ß-site APP cleaving enzyme (BACE), Lipoprotein receptor related protein 1 (LRP1), Cerebral amyloid angiopathy (CAA), P-gp inhibitor, Rifampicin, GSK188909, α-synuclein oligomers, C3435T TT polymorphism, Progressive supranuclear palsy (PSP), Multisystem atrophy (MSA), Pergolide, pramipexol, budipine, Huntington disease (HD), Creutzfeldt-Jakob Disease (CJD), Amyotrophic lateral sclerosis (ALS), Major depressive disorder (MDD)
Abstract: P-glycoprotein (P-gp) at the blood-brain barrier (BBB) functions as an active efflux pump by extruding a wide range of substrates from the brain. This is important for maintaining loco-regional homeostasis and for protecting the brain against blood-borne toxic substances. Altered P-gp function seems to be involved in the pathophysiology of neurodegenerative disease and various neurological and psychiatric disorders. Positron emission tomography (PET) with the radiotracer 11C-verapamil (VPM-PET) is a validated technique allowing measurement of P-gp function at the human BBB. In this review, we highlight changes of P-gp function, as measured with VPM-PET, in aging and in the pathogenesis and progression of neurodegenerative disease, as well as their role in depressive disorders.
Export Options
About this article
Cite this article as:
L. Bartels A., L. de Klerk O., Kortekaas R., J. de Vries J. and L. Leenders K., 11C-verapamil to Assess P-gp Function in Human Brain During Aging,Depression and Neurodegenerative Disease, Current Topics in Medicinal Chemistry 2010; 10 (17) . https://dx.doi.org/10.2174/156802610792928059
DOI https://dx.doi.org/10.2174/156802610792928059 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Possible Usefulness of Growth Hormone/Insulin-like Growth Factor-I Axis in Alzheimer’s Disease Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets Migraine and Coronary Artery Disease: An Open Study on the Genetic Polymorphism of the 5, 10 Methylenetetrahydrofolate (MTHFR) and Angiotensin I-Converting Enzyme (ACE) Genes
Central Nervous System Agents in Medicinal Chemistry Drug Choices and Advancements for Managing Depression in Parkinson's Disease
Current Neuropharmacology SLC1 Glutamate Transporters and Diseases: Psychiatric Diseases and Pathological Pain
Current Molecular Pharmacology Indications for Heart Transplantation in Congenital Heart Disease
Current Cardiology Reviews Carbon Nano Tubes: Novel Drug Delivery System in Amelioration of Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening Effects of Transition Metals in the Conversion Mechanism of Prion Protein and in the Pathogenesis of Prion Diseases
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Midlife Modifiable Risk Factors for Dementia: A Systematic Review and Meta-analysis of 34 Prospective Cohort Studies
Current Alzheimer Research Patent Selections:
Recent Patents on Regenerative Medicine AMPK in Neurodegenerative Diseases: Implications and Therapeutic Perspectives
Current Drug Targets Vascular Oxidative Stress and Mitochondrial Failure in the Pathobiology of Alzheimer’s Disease: A New Approach to Therapy
CNS & Neurological Disorders - Drug Targets A Review on the Effects of Testosterone Supplementation in Hypogonadal Men with Cognitive Impairment
Current Drug Targets Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Role of the APP Non-Amyloidogenic Signaling Pathway and Targeting α-Secretase as an Alternative Drug Target for Treatment of Alzheimers Disease
Current Medicinal Chemistry The Glutamatergic Hypothesis for Down Syndrome: The Potential Use of N-Methyl-D-Aspartate Receptor Antagonists to Enhance Cognition and Decelerate Neurodegeneration
CNS & Neurological Disorders - Drug Targets Neurokinin Peptides and Neurokinin Receptors as Potential Therapeutic Intervention Targets of Basal Ganglia in the Prevention and Treatment of Parkinsons Disease
Current Drug Targets Compensatory Shift of Subcallosal Area and Paraterminal Gyrus White Matter Parameters on DTI in Patients with Alzheimer Disease
Current Alzheimer Research Neuroimaging Findings Related to Behavioral Disturbances in Alzheimer's Disease: A Systematic Review
Current Alzheimer Research Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke
Current Neurovascular Research Kinases as Targets for Parkinson's Disease: From Genetics to Therapy
CNS & Neurological Disorders - Drug Targets